Home > Publications Database > Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. > print

001     269254
005     20240428003926.0
024 7 _ |a 10.1038/s41591-024-02886-y
|2 doi
024 7 _ |a pmid:38622249
|2 pmid
024 7 _ |a pmc:PMC11031390
|2 pmc
024 7 _ |a 1078-8956
|2 ISSN
024 7 _ |a 1546-170X
|2 ISSN
024 7 _ |a altmetric:162463438
|2 altmetric
037 _ _ |a DZNE-2024-00502
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Pagano, Gennaro
|0 0000-0002-6247-8988
|b 0
245 _ _ |a Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
260 _ _ |a New York, NY
|c 2024
|b Nature America Inc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1714043793_4332
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Prasinezumab, a monoclonal antibody that binds aggregated α-synuclein, is being investigated as a potential disease-modifying therapy in early-stage Parkinson's disease. Although in the PASADENA phase 2 study, the primary endpoint (Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) sum of Parts I + II + III) was not met, prasinezumab-treated individuals exhibited slower progression of motor signs than placebo-treated participants (MDS-UPDRS Part III). We report here an exploratory analysis assessing whether prasinezumab showed greater benefits on motor signs progression in prespecified subgroups with faster motor progression. Prasinezumab's potential effects on disease progression were assessed in four prespecified and six exploratory subpopulations of PASADENA: use of monoamine oxidase B inhibitors at baseline (yes versus no); Hoehn and Yahr stage (2 versus 1); rapid eye movement sleep behavior disorder (yes versus no); data-driven subphenotypes (diffuse malignant versus nondiffuse malignant); age at baseline (≥60 years versus <60 years); sex (male versus female); disease duration (>12 months versus <12 months); age at diagnosis (≥60 years versus <60 years); motor subphenotypes (akinetic-rigid versus tremor-dominant); and motor subphenotypes (postural instability gait dysfunction versus tremor-dominant). In these subpopulations, the effect of prasinezumab on slowing motor signs progression (MDS-UPDRS Part III) was greater in the rapidly progressing subpopulations (for example, participants who were diffuse malignant or taking monoamine oxidase B inhibitors at baseline). This exploratory analysis suggests that, in a trial of 1-year duration, prasinezumab might reduce motor progression to a greater extent in individuals with more rapidly progressing Parkinson's disease. However, because this was a post hoc analysis, additional randomized clinical trials are needed to validate these findings.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Antiparkinson Agents
|2 NLM Chemicals
650 _ 7 |a Monoamine Oxidase
|0 EC 1.4.3.4
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Parkinson Disease
|2 MeSH
650 _ 2 |a Tremor: drug therapy
|2 MeSH
650 _ 2 |a Antiparkinson Agents: therapeutic use
|2 MeSH
650 _ 2 |a Monoamine Oxidase: therapeutic use
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
700 1 _ |a Taylor, Kirsten I
|b 1
700 1 _ |a Anzures Cabrera, Judith
|b 2
700 1 _ |a Simuni, Tanya
|b 3
700 1 _ |a Marek, Kenneth
|b 4
700 1 _ |a Postuma, Ronald B
|b 5
700 1 _ |a Pavese, Nicola
|b 6
700 1 _ |a Stocchi, Fabrizio
|b 7
700 1 _ |a Brockmann, Kathrin
|0 P:(DE-2719)2811916
|b 8
700 1 _ |a Svoboda, Hanno
|b 9
700 1 _ |a Trundell, Dylan
|b 10
700 1 _ |a Monnet, Annabelle
|b 11
700 1 _ |a Doody, Rachelle
|b 12
700 1 _ |a Fontoura, Paulo
|b 13
700 1 _ |a Kerchner, Geoffrey A
|b 14
700 1 _ |a Brundin, Patrik
|b 15
700 1 _ |a Nikolcheva, Tania
|b 16
700 1 _ |a Bonni, Azad
|b 17
700 1 _ |a Investigators, PASADENA
|b 18
|e Collaboration Author
700 1 _ |a Group, Prasinezumab Study
|b 19
|e Collaboration Author
773 _ _ |a 10.1038/s41591-024-02886-y
|g Vol. 30, no. 4, p. 1096 - 1103
|0 PERI:(DE-600)1484517-9
|n 4
|p 1096 - 1103
|t Nature medicine
|v 30
|y 2024
|x 1078-8956
856 4 _ |u https://pub.dzne.de/record/269254/files/DZNE-2024-00502%20SUP1.pdf
856 4 _ |u https://pub.dzne.de/record/269254/files/DZNE-2024-00502%20SUP2.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/269254/files/DZNE-2024-00502.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/269254/files/DZNE-2024-00502%20SUP1.pdf?subformat=pdfa
856 4 _ |x pdfa
|u https://pub.dzne.de/record/269254/files/DZNE-2024-00502%20SUP2.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/269254/files/DZNE-2024-00502.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:269254
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2811916
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-29
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT MED : 2022
|d 2023-08-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-29
915 _ _ |a DEAL Nature
|0 StatID:(DE-HGF)3003
|2 StatID
|d 2023-08-29
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-29
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-29
915 _ _ |a IF >= 80
|0 StatID:(DE-HGF)9980
|2 StatID
|b NAT MED : 2022
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-29
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-08-29
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-29
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1210000
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21